Methodology
Methodology Guidelines
The primary objective of EUnetHTA Methdological guidelines is to focus on methdological challenges that are encountered by HTA assessors while performing relative effectiveness assessments of pharmaceuticals or non-pharmaceutical health technologies.
The guidelines represent a consolidated view of non-binding recommendations of EUnetHTA network members and in no case are an official opinion of the participating institutions or individuals.
Guidelines in italics = under revision
Title | Version | Last Update | Link |
|---|---|---|---|
Comparators & Comparisons: Criteria for the choice of the most appropriate comparator(s) | 2.0 | 2015 | PDF Version |
Comparators & Comparisons: Direct and indirect comparisons | 2.0 | 2015 | PDF Version |
Endpoints used for Relative Effectiveness Assessment Health: related quality of life and utility measures | 2.0 | 2015 | PDF Version |
Endpoints used for Relative Effectiveness Assessment: Clinical Endpoints | 2.0 | 2015 | PDF Version |
Endpoints used for Relative Effectiveness Assessment: Composite endpoints | 2.0 | 2015 | PDF Version |
Endpoints used in Relative Effectiveness Assessment: Safety | 2.0 | 2015 | PDF Version |
Endpoints used in Relative Effectiveness Assessment: Surrogate Endpoints | 2.0 | 2015 | PDF Version |
Internal validity of non-randomised studies (NRS) on interventions | 1.0 | 2015 | PDF Version |
Internal validity of randomised controlled trials | 2.0 | 2015 | PDF Version |
Levels of Evidence – Applicability of evidence for the context of a relative effectiveness assessment | 2.0 | 2015 | PDF Version |
Meta-analysis of diagnostic test accuracy studies | 1.0 | 2014 | PDF Version |
Methods for health economic evaluations – A guideline based on current practices in Europe | 1.0 | 2015 | PDF Version |
Personalised Medicine and Co-Dependent Technologies | 1.0 | 2015 | PDF Version |
Practical considerations when critically assessing economic evaluations. Guidance document | 1.0 | 2020 | PDF Version |
Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness | 2.0 | 2019 | PDF Version |
Therapeutic medical devices | 1.0 | 2015 | PDF Version |
Guidelines under development
Title | Status | Planned publication |
|---|---|---|
Critical assessment of clinical evaluations | Concept | 2020 |
The production of the EUnetHTA Guidelines has been successfully coordinated by EUnetHTA JA1 WP5 (HAS), EUnetHTA JA2 WP7 SG3 (IQWiG) and EUnetHTA JA3 WP6B (KCE).
If you wish to provide feedback on an existing EUnetHTA Methodological Guideline, please make use of the below template:
PLEG guidance
The following documentation has been produced during JA1 and JA2, as outputs of EUnetHTA JA1 and JA2 WP7, under the coordination of HAS.
Position Paper on research recommendations for AEG
Position Paper on study design for AEG
Selection Prioritisation Criteria for AEG
